CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 26 enrolled
Drug / intervention
cediranib maleate +1 moredrug
Likely dose
Cediranib maleate orally, dose not specifiedAI-extracted
Key inclusion· 6
  • ✓Histologically or cytologically confirmed stage IV breast cancer, including recurrent and inflammatory carcinoma subtypes
  • ✓Measurable disease: ≥20 mm by conventional imaging or ≥10 mm by spiral CT
  • ✓Refractory breast cancer with clinical tumor progression on most recent hormonal/chemotherapy/trastuzumab therapy; up to 3 prior chemotherapy regimens for metastatic disease allowed
  • ✓Life expectancy >3 months
Key exclusion· 9
  • ✕Brain metastases; baseline head CT or MRI required
  • ✕Prior anti-angiogenesis therapy
  • ✕Chemotherapy, radiotherapy, or major surgery within 4 weeks (6 weeks for nitrosoureas/mitomycin C)
  • ✕Investigational agents within past 30 days

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00244881
NCT00244881Phase 2Completed
CompareCT.gov

A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)

National Cancer Institute (NCI)·interventional·Posted Oct 27, 2005·Updated Dec 7, 2015

In Brief

A Phase 2 clinical trial evaluating cediranib maleate and laboratory biomarker analysis for Male Breast Cancer and 2 related conditions. Completed, enrolled 26 participants across 1 site.

Detailed Summary

AZD2171 (cediranib maleate) may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. This phase II trial is studying how well AZD2171 works in treating patients with refractory stage IV breast cancer

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMale Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 27, 2005
Enrollment StartSep 1, 2005
Primary CompletionAug 1, 2007
Study CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 20.7 years ago

Interventions

cediranib maleatedrug

Given orally

laboratory biomarker analysisother

Correlative studies